All In Biotech

Drug Trial Radar · NCT06999083

A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants

A Phase Ia, Randomized, Double-blind, Placebo-controlled, Single Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HB0043 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Jun 3, 2025

Primary completion

Feb 12, 2026

Study completion Apr 30, 2026

Sponsor

Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to investigate the safety and tolerability of HB0043 in healthy subjects following single-dose.

Conditions

  • Healthy

Interventions

  • HB0043Drug

    HB0043 Drug Product

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects with drug related adverse events (AEs)Time frame: Up to 1200 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research , Grafton, Auckland, 3 Ferncroft Street,

    Auckland, Grafton, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.